B
BioGenCell
Biotech & Life Sciences · Hod Hasharon, Israel · Founded 2008
Uses stem cells from the patient’s own blood to treat microvascular diseases and designs cellular therapies MoreLess
BioGenCell is a biotechnology company specializing in personalized cell therapy for vascular diseases. The company leverages a unique combination of immunology and stem cell technology to develop treatments that can be administered within a day in any clinic. BioGenCell primarily serves patients suffering from life-threatening vascular conditions, offering a groundbreaking technology for the automated production of personalized stem cell therapies. Operating in the biotechnology and pharmaceutical market, BioGenCell's business model focuses on providing safe, effective, and accessible treatments. The company generates revenue through the development and sale of its proprietary therapies, targeting a wide range of degenerative vascular diseases. BioGenCell's mission is to shape the future of healthcare by making personalized stem cell therapy available on demand, ensuring high standards of safety and efficacy. Keywords: personalized therapy, stem cells, vascular diseases, immunology, biotechnology, automated production, rapid treatment, degenerative diseases, healthcare innovation, patient-friendly.
Company overview
BioGenCell company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2008
- Headquarters
- Hod Hasharon, Israel
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 68.6
Valuation & funding
BioGenCell funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | May 2022 | $16M | $64M | Marius Nacht | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 14 |
| 2025 | 15 |
| 2024 | 16 |
| 2023 | 13 |
| 2022 | 10 |
| 2021 | 7 |
Growth signals
BioGenCell website traffic
Latest recorded traffic for BioGenCell is 1.5K monthly website visits, up 417.2% over the last three months. BioGenCell's team declined 6.7% over the past year.
Comparisons
BioGenCell compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
BioGenCell's talent
Source: Dealroom Talent Intelligence.
Investors
1 investor on BioGenCell's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where BioGenCell has talent and traffic
team presence
In the news
Latest news about BioGenCell
Recent press, funding announcements, and product moves mentioning BioGenCell — open to read from the original sources.
Market sentiment
What the market is saying about BioGenCell
An AI-synthesized read of the highest-engagement posts about BioGenCell on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioGenCell’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.